Short Interest in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Drops By 77.9%

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 8,194 shares, a decline of 77.9% from the July 30th total of 37,127 shares. Based on an average daily trading volume, of 64,625 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.2% of the company’s stock are sold short.

Regentis Biomaterials Stock Performance

Shares of RGNT traded down $0.01 during mid-day trading on Thursday, hitting $2.06. 8,211 shares of the company traded hands, compared to its average volume of 2,121,063. The business has a 50 day moving average of $2.68 and a 200 day moving average of $2.93. Regentis Biomaterials has a 1-year low of $1.23 and a 1-year high of $15.50.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials as of its most recent SEC filing.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.